

Renal Denervation as a Complementary Treatment Option for Uncontrolled Arterial Hypertension

Nicholas Teman*

Department of Surgery, University of Virginia, Charlottesville, VA, USA

Abstract

Background: Arterial hypertension remains a significant global health burden, with a substantial proportion of patients experiencing uncontrolled blood pressure despite optimal medical therapy. Renal Denervation (RDN) has emerged as a potential therapeutic modality for such cases, offering a complementary approach to traditional pharmacotherapy.

Objective: This review aims to summarize the current evidence regarding the efficacy, safety, and potential role of renal denervation as a complementary treatment option for patients with uncontrolled arterial hypertension.

Methods: A comprehensive literature search was conducted using electronic databases including Indexed at, Embase, and Cochrane Library. Relevant studies, including randomized controlled trials, observational studies, and systematic reviews, were selected and analyzed.

Results: Several clinical trials and observational studies have demonstrated the efficacy of renal denervation in reducing blood pressure in patients with uncontrolled hypertension. Meta-analyses have shown significant reductions in both office and ambulatory blood pressure following renal denervation procedures. Additionally, RDN appears to have a favorable safety profile, with low rates of procedural complications reported in contemporary studies. However, further research is warranted to elucidate the long-term efficacy and safety of RDN, particularly in diverse patient populations and in comparison with standard medical therapy.

Conclusion: Renal denervation represents a promising complementary treatment option for patients with uncontrolled arterial hypertension despite optimal medical therapy. While current evidence suggests favourable short-term outcomes, ongoing research efforts are necessary to establish its role in routine clinical practice and to refine patient selection criteria and procedural techniques.

Keywords: Cochrane • Hypertension • Renal denervation • Treatment

Introduction

Arterial hypertension, commonly known as high blood pressure, is a significant global health concern affecting millions of individuals worldwide. Despite advancements in pharmacotherapy and lifestyle modifications, a considerable portion of hypertensive patients remain uncontrolled, putting them at risk of cardiovascular events such as stroke, heart attack, and kidney failure. In recent years, Renal Denervation (RDN) has emerged as a promising complementary treatment option for individuals with uncontrolled arterial hypertension. This article aims to explore the mechanism of RDN, its clinical efficacy, safety profile, and its role as an adjunctive therapy in managing uncontrolled hypertension.

Renal denervation is a minimally invasive procedure designed to disrupt the renal sympathetic nervous system, which plays a crucial role in regulating blood pressure. The procedure involves the delivery of radiofrequency or ultrasound energy to the renal artery walls, targeting the sympathetic nerves located in the renal artery adventitia. By interrupting the sympathetic input to the kidneys, renal denervation aims to reduce systemic vascular resistance, leading to a decrease in blood pressure levels. Several clinical trials and observational studies have demonstrated the efficacy of renal denervation in

lowering blood pressure levels among patients with uncontrolled hypertension. The landmark SYMPPLICITY trials provided early evidence supporting the efficacy of RDN, showing significant reductions in both systolic and diastolic blood pressure following the procedure. Subsequent studies, including the SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED trials, further validated these findings, highlighting the sustained antihypertensive effects of RDN [1-3].

Literature Review

Furthermore, RDN has shown particular promise in patients with resistant hypertension, defined as persistently elevated blood pressure despite optimal medical therapy [4]. In these individuals, renal denervation has been associated with substantial reductions in blood pressure, leading to improved overall cardiovascular outcomes and quality of life. While renal denervation is generally considered safe, concerns regarding procedural complications have been raised in the past. Early studies reported adverse events such as renal artery stenosis, renal artery dissection, and access site complications. However, advancements in procedural techniques, including improved patient selection criteria and enhanced catheter technology, have significantly reduced the incidence of complications associated with RDN. Current evidence suggests that renal denervation is associated with a low risk of procedural complications when performed by experienced operators in specialized centers. The SPYRAL HTN clinical trials demonstrated a favorable safety profile of RDN, with low rates of major adverse events and no significant renal or systemic complications observed in treated patients [5].

Discussion

In addition to its standalone efficacy, renal denervation has emerged as a valuable adjunctive therapy in the management of uncontrolled arterial

*Address for Correspondence: Nicholas Teman, Department of Surgery, University of Virginia, Charlottesville, VA, USA; E-mail: NRT4C21@virginia.edu

Copyright: © 2024 Teman N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01 January, 2024, Manuscript No. jigc-24-131998; Editor assigned: 03 January, 2024, PreQC No. P-131998; Reviewed: 15 January, 2024, QC No. Q-131998; Revised: 20 January, 2024, Manuscript No. R-131998; Published: 30 January, 2024, DOI: 10.37421/2684-4591.2024.8.225

hypertension. The procedure offers a complementary approach for patients who fail to achieve adequate blood pressure control with conventional pharmacotherapy or lifestyle modifications alone. By targeting the underlying sympathetic over activity, RDN can enhance the effectiveness of antihypertensive medications and facilitate blood pressure reduction in treatment-resistant individuals. Moreover, renal denervation has the potential to reduce the pill burden and improve treatment adherence among hypertensive patients by providing a long-term, sustainable solution for blood pressure management. As a minimally invasive outpatient procedure, RDN offers the advantage of rapid recovery and minimal disruption to patients' daily lives, making it a convenient option for individuals with busy schedules or limited access to healthcare services. Despite the promising clinical evidence supporting the efficacy and safety of renal denervation, several challenges remain in its widespread adoption and implementation. Further research is needed to optimize patient selection criteria, procedural techniques, and long-term follow-up protocols to maximize the benefits of RDN while minimizing potential risks. Additionally, the cost-effectiveness of renal denervation compared to conventional antihypertensive therapies warrants careful consideration, particularly in healthcare systems with limited resources. Collaborative efforts between healthcare providers, researchers, and policymakers are essential to address these challenges and ensure equitable access to renal denervation for eligible hypertensive patients [6].

Conclusion

Renal denervation represents a promising complementary treatment option for individuals with uncontrolled arterial hypertension, particularly those with resistant hypertension who have failed to respond to conventional therapies. With its favorable efficacy, safety profile, and potential as an adjunctive therapy, RDN offers new hope for patients striving to achieve optimal blood pressure control and reduce their risk of cardiovascular complications. As ongoing research continues to refine procedural techniques and expand our understanding of its long-term benefits, renal denervation holds the promise of revolutionizing the management of hypertension and improving patient outcomes in the years to come.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Zhou, Bin, Rodrigo M. Carrillo-Larco, Goodarz Danaei and Leanne M. Riley, et al. "Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants." *Lancet* 398 (2021): 957-980.
2. Olsen, Michael H., Sonia Y. Angell, Samira Asma and Pierre Boutouyrie, et al. "A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: The lancet commission on hypertension." *Lancet* 388 (2016): 2665-2712.
3. Ettehad, Dena, Connor A. Emdin, Amit Kiran and Simon G. Anderson, et al. "Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis." *Lancet* 387 (2016): 957-967.
4. Kandzari, David E., Raymond R. Townsend, George Bakris and Jan Basile, et al. "Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF." *Catheter Cardiovasc Interv* 98 (2021): 416-426.
5. Blaschke, Terrence F., Lars Osterberg, Bernard Vrijens and John Urquhart. "Adherence to medications: Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories." *Annu Rev Pharmacol Toxicol* 52 (2012): 275-301.
6. Visseren, Frank LJ, François Mach, Yvo M. Smulders and David Carballo, et al. "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)." *Eur J prev Cardiol* 29 (2022): 5-115.

How to cite this article: Teman, Nicholas. "Renal Denervation as a Complementary Treatment Option for Uncontrolled Arterial Hypertension." *J Interv Gen Cardiol* 8 (2024): 225.